Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Preferential Issue

Shukra Pharmaceuticals allotted 17.35 lakh preferential equity shares at Rs 35.56 to five investors. The raise totals about Rs 6.17 Crore.

Value

₹6.17 Cr

Shukra Pharmaceuticals Other Announcement

Shukra Medtech confirmed no deviation in the use of funds from its preferential convertible warrant issue. The company received ₹10.46 Crore, 75% of the consideration, from allottees.

Value

₹10.46 Cr

Shukra Pharmaceuticals Q2 FY27 Results: Net Profit ₹12.7 Cr, Up 429.2% YoY

Shukra Pharmaceuticals Ltd reported revenue from operations of ₹44.2 Cr (+649.2% YoY) and net profit of ₹12.7 Cr (+429.2% YoY) for Q2 FY27.

Key figure

Net profit ₹12.7 Cr · +429.2% YoY

Shukra Pharmaceuticals Board Meeting Date

Shukra Medtech Limited has scheduled a board meeting on November 3, 2026, to consider and approve its unaudited financial results for the quarter ended September 2026.

Shukra Pharmaceuticals Other Announcement

Shukra Medtech submitted a revised CA certificate to NSE for its name and symbol change application. The filing requests final exchange approval for the corporate rename.